Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART
Alexander O. Pasternak, … , Jan M. Prins, Ben Berkhout
Alexander O. Pasternak, … , Jan M. Prins, Ben Berkhout
Published February 25, 2020
Citation Information: JCI Insight. 2020;5(6):e134196. https://doi.org/10.1172/jci.insight.134196.
View: Text | PDF
Research Article AIDS/HIV Virology

Cell-associated HIV-1 RNA predicts viral rebound and disease progression after discontinuation of temporary early ART

  • Text
  • PDF
Abstract

Plasma viral load (VL) and CD4+ T cell count are widely used as biomarkers of HIV type 1 (HIV-1) replication, pathogenesis, and response to antiretroviral therapy (ART). However, the clinical potential of cell-associated (CA) HIV-1 molecular markers is much less understood. Here, we measured CA HIV-1 RNA and DNA in HIV-infected individuals treated with temporary ART initiated during primary HIV-1 infection. We demonstrate substantial predictive value of CA RNA for (a) the virological and immunological response to early ART, (b) the magnitude and time to viral rebound after discontinuation of early ART, and (c) disease progression in the absence of treatment. Remarkably, when adjusted for CA RNA, plasma VL no longer appeared as an independent predictor of any clinical endpoint in this cohort. The potential of CA RNA as an HIV-1 clinical marker, in particular as a predictive biomarker of virological control after stopping ART, should be explored in the context of HIV-1 curative interventions.

Authors

Alexander O. Pasternak, Marlous L. Grijsen, Ferdinand W. Wit, Margreet Bakker, Suzanne Jurriaans, Jan M. Prins, Ben Berkhout

×

Figure 4

Pre-ART predictors of virological suppression at 12 weeks of early ART.

Options: View larger image (or click on image) Download as PowerPoint
Pre-ART predictors of virological suppression at 12 weeks of early ART.
...
Plasma VL, CA HIV US and MS RNA, total HIV DNA, CD4+ count, and CD4/CD8 ratio, measured at the start of early ART, were compared between participants with undetectable (n = 19, blue dots) and detectable (n = 24, red dots) plasma VL at 12 weeks of early ART. P values were calculated using Mann-Whitney U tests. Open circles depict undetectable values, censored to 50% of assay detection limits.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts